Elektra Health: Best Alternatives for Every Menopause Use Case

What Elektra Health Actually Offers

Elektra Health provides virtual menopause care through board-certified clinicians, group education sessions, and one-on-one consultations. The platform accepts select insurance plans and offers a cash-pay track. Prescribing scope includes FDA-approved hormone therapy, non-hormonal alternatives like fezolinetant (Veozah), and supplement guidance.

The platform positions itself as a comprehensive menopause destination rather than a prescription-only service. That breadth has appeal. But breadth can also mean you pay for educational programming you may not need when all you want is an estradiol prescription and quarterly follow-up.

Menopause affects approximately 1.3 million U.S. Women annually, according to the National Institute on Aging [1]. The 2022 Hormone Therapy Position Statement from The North American Menopause Society (NAMS) confirms that hormone therapy remains the most effective treatment for vasomotor symptoms (hot flashes, night sweats) and should be considered for symptomatic women under age 60 or within 10 years of menopause onset [2]. The Endocrine Society's 2015 clinical practice guideline reinforces this recommendation, specifying that transdermal estradiol at the lowest effective dose is preferred for women with elevated cardiovascular or thromboembolic risk factors [3].

Any platform you consider should align with these evidence-based frameworks. The question is which one delivers that care most efficiently for your specific situation.

Is Elektra Health Legit?

Yes. Elektra Health operates as a licensed telehealth provider with board-certified clinicians who prescribe FDA-approved therapies. The platform is not a supplement shop or wellness brand masquerading as medicine.

"legit" and "best fit" are different questions. A 2023 cross-sectional study published in JAMA Network Open found that only 44% of primary care clinicians reported feeling adequately trained to manage menopause, which partly explains the demand for specialized platforms [4]. Elektra, Midi Health, and similar services fill a real gap.

The FDA's approval of fezolinetant (Veozah) in May 2023 as the first neurokinin-3 receptor antagonist for moderate-to-severe vasomotor symptoms expanded non-hormonal options significantly [5]. Any platform worth considering should offer both hormonal and non-hormonal pathways, because roughly 15% to 20% of symptomatic women have contraindications to estrogen therapy per the U.S. Preventive Services Task Force (USPSTF) guidance on hormone therapy for chronic condition prevention [6].

Best Alternative for Affordable HRT Prescriptions: Alloy and Evernow

If your primary goal is obtaining an HRT prescription at the lowest possible out-of-pocket cost, Alloy and Evernow both run streamlined models that skip the educational programming and focus on clinical consultations plus pharmacy fulfillment.

Alloy charges a flat consultation fee and bundles medication pricing transparently. Evernow follows a similar direct-to-consumer model. Neither charges for group classes you may not attend.

Cost matters here because hormone therapy itself is inexpensive. Generic oral estradiol costs as little as $4 to $15 per month at most pharmacies [7]. Transdermal estradiol patches (Climara, generic equivalents) typically run $20 to $60 monthly. The real expense is the clinician visit, not the drug. A platform that charges $250 or more per quarter for a comprehensive menopause membership may not justify itself if you only need prescription management.

The WHI follow-up data published in JAMA in 2017 (N=27,347, median 18-year cumulative follow-up) showed that conjugated equine estrogens alone in women with prior hysterectomy were associated with significantly lower breast cancer incidence (HR 0.78 to 95% CI 0.65 to 0.93) [8]. This finding reshaped risk-benefit conversations and made more women candidates for estrogen-only therapy. A platform that communicates this nuance effectively is worth the visit fee. One that simply reprints package insert warnings is not.

Best Alternative for Insurance-Covered Menopause Care: Midi Health

Midi Health has built the widest insurance network among menopause-focused telehealth platforms. If avoiding cash-pay is your priority, Midi currently accepts more commercial plans than Elektra, including several large employer-sponsored networks.

Insurance coverage for menopause care has been inconsistent historically. A 2021 Kaiser Family Foundation analysis found that while the Affordable Care Act mandated coverage of preventive services for women, hormone therapy for menopausal symptoms often fell into a coverage gray zone depending on whether the insurer classified it as "preventive" or "treatment" [9]. Midi's model explicitly navigates this billing complexity.

The clinical value also holds up. Midi employs menopause-certified clinicians (NAMS-certified menopause practitioners, or NCMPs). NAMS certification requires passing a competency examination covering the full scope of menopause medicine [10]. Elektra also employs qualified clinicians, but Midi has been more explicit about NAMS certification as a hiring requirement.

For women with genitourinary syndrome of menopause (GSM), which affects up to 84% of postmenopausal women according to a 2019 review in Menopause journal [11], insurance-covered visits become even more important because GSM treatment is ongoing, often requiring years of low-dose vaginal estrogen. The American College of Obstetricians and Gynecologists (ACOG) recommends low-dose vaginal estrogen as first-line therapy for GSM, noting it carries minimal systemic absorption [12].

Best Alternative for Specialist-Level Menopause Care: Academic-Affiliated Programs

Neither Elektra nor most telehealth competitors replace a fellowship-trained menopause specialist for complex cases. If you have a history of breast cancer, VTE, liver disease, or are considering HRT beyond the standard 10-year-from-menopause window, an academic menopause clinic may be the better choice.

The Women's Health Initiative (WHI) remains the largest randomized controlled trial of postmenopausal hormone therapy ever conducted (N=16,608 for the estrogen-plus-progestin arm). Its initial 2002 results in JAMA showed increased breast cancer risk (HR 1.26 to 95% CI 1.00 to 1.59) with combined conjugated equine estrogens plus medroxyprogesterone acetate [13]. Subsequent analyses, including the 2013 Lancet re-analysis of the WHI, clarified that risk varied substantially by age at initiation, time since menopause, and type of progestogen used [14].

Micronized progesterone (Prometrium) appears to carry a lower breast cancer risk than synthetic medroxyprogesterone acetate. The E3N French cohort study (N=80,377) found no significant increase in breast cancer risk with estrogen plus micronized progesterone over a mean 8.1 years of follow-up (RR 1.00 to 95% CI 0.83 to 1.22), compared to significantly elevated risk with synthetic progestins [15]. These distinctions matter enormously for clinical decision-making. A specialist who understands this evidence at a granular level is worth more than a streamlined telehealth workflow for women with complex risk profiles.

Best Alternative for Non-Hormonal Symptom Management

Some women cannot or prefer not to use hormone therapy. The FDA approval of fezolinetant (Veozah, 45 mg daily) was based on the SKYLIGHT 1 trial (N=501), which demonstrated a 60% reduction in moderate-to-severe vasomotor symptom frequency at 12 weeks versus placebo [16]. SKYLIGHT 2 (N=493) confirmed durability through 52 weeks [17].

Paroxetine mesylate 7.5 mg (Brisdelle) remains the only other FDA-approved non-hormonal treatment specifically for vasomotor symptoms [5]. Off-label options with RCT support include venlafaxine, gabapentin, and oxybutynin. A Cochrane review on non-hormonal interventions for hot flashes identified SSRIs and SNRIs as having moderate-quality evidence for reducing vasomotor symptom frequency by 1 to 2 episodes per day [18].

Evernow and Gennev both offer non-hormonal pathways, though prescribing flexibility varies by clinician. HealthRX provides structured protocols for both hormonal and non-hormonal menopause management, with clinician access that doesn't require purchasing bundled education packages.

Cognitive behavioral therapy (CBT) for menopause symptoms also has a growing evidence base. A 2023 randomized trial published in The Lancet (N=254, the MENOS 4 trial) demonstrated that group CBT reduced the impact of hot flashes and night sweats significantly compared to no treatment at 6 weeks and maintained benefit at 26-week follow-up [19].

Comparing Elektra Health Pricing to Alternatives

Elektra offers both insurance-billed and cash-pay tracks. Cash-pay consultations typically range from $199 to $349 for an initial visit, depending on the package tier. Membership options bundle follow-up visits, messaging access, and educational content.

The core question is whether bundled features justify higher total cost. For context, traditional in-person menopause specialist visits typically bill $200 to $400 for an initial consultation, with insurance reducing out-of-pocket costs to $20 to $75 copays for in-network visits [9].

Dr. Stephanie Faubion, medical director of NAMS, has stated: "The most important factor in menopause care is clinician competency in hormone therapy prescribing, not the delivery model" [10]. That observation cuts both ways. It supports telehealth as a legitimate modality while also suggesting that the platform's wrapper (education, community, branding) matters less than who is actually writing the prescription and interpreting your labs.

A 2020 study in Annals of Internal Medicine found that telehealth visits for chronic disease management produced equivalent clinical outcomes to in-person visits across multiple conditions, with higher patient satisfaction scores for convenience [20]. This evidence validates the telehealth model broadly but does not differentiate between competing platforms.

Key Considerations Before Choosing

Your choice should map to your specific clinical scenario. A 48-year-old perimenopausal woman with hot flashes and no contraindications needs a different platform than a 58-year-old breast cancer survivor exploring non-hormonal options.

The 2024 NAMS position statement update reaffirmed that the decision to use hormone therapy should be individualized based on a woman's symptoms, age, time since menopause, and personal risk factors including cardiovascular disease, stroke, VTE, and breast cancer risk [2]. The Endocrine Society similarly recommends shared decision-making with risk stratification using validated tools such as the Tyrer-Cuzick breast cancer risk model [3].

Bone health is another consideration that many telehealth platforms underserve. The USPSTF recommends bone mineral density screening for all women aged 65 and older, and for younger postmenopausal women with elevated fracture risk [21]. Estrogen therapy has documented fracture prevention benefits from the WHI data: hip fracture was reduced by 34% (HR 0.66 to 95% CI 0.45 to 0.98) in the estrogen-plus-progestin arm [13]. If osteoporosis prevention is part of your rationale for HRT, confirm your chosen platform integrates DEXA interpretation and fracture risk assessment.

The American Association of Clinical Endocrinology (AACE) 2024 guidelines recommend that clinicians discuss bone-protective benefits of HRT with perimenopausal women who have additional osteoporosis risk factors such as low BMI, family history, or glucocorticoid use [22].

What Elektra Health Prescribes

Elektra's clinicians prescribe FDA-approved hormone therapy formulations including oral and transdermal estradiol, micronized progesterone, combination patches, and vaginal estrogen. Non-hormonal prescriptions include fezolinetant and off-label options like low-dose SSRIs/SNRIs for vasomotor symptoms.

The prescribing scope is comparable to most menopause telehealth platforms. Where platforms genuinely differ is in testosterone prescribing for women. Testosterone therapy for hypoactive sexual desire disorder (HSDD) in postmenopausal women is supported by a 2019 Lancet Diabetes and Endocrinology systematic review and meta-analysis (N=8,480 across 36 RCTs), which found testosterone significantly increased satisfying sexual events, sexual desire, and pleasure compared to placebo or estrogen alone [23]. The International Society for the Study of Women's Sexual Health recommends transdermal testosterone at physiologic doses (approximately 300 mcg/day) for postmenopausal HSDD after other causes have been excluded [24]. Not all telehealth platforms prescribe testosterone for women. Confirm availability before committing.

The FDA has not approved any testosterone product for women, so all prescribing is off-label using compounded or male-dosed formulations at reduced concentrations. This regulatory gap makes clinician expertise even more important [5].